MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/120/0.2/20.09.24 | Market Closed - Börse Stuttgart 19:59:17 02/07/2024 BST | ||
| 4.65 EUR | -10.75% |
|
| Current month | -3.93% | ||
| 1 month | +34.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 02/07/24 | 4.65 | -10.75% |
| 01/07/24 | 5.21 | +7.64% |
| 28/06/24 | 4.84 | -3.59% |
| 27/06/24 | 5.02 | -0.79% |
| 26/06/24 | 5.06 | -8.00% |
Delayed Quote Börse Stuttgart
Last update July 02, 2024 at 07:59 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB4RGP |
| ISIN | DE000MB4RGP3 |
| Date issued | 23/03/2023 |
| Strike | 120 $ |
| Maturity | 20/09/2024 (80 Days) |
| Parity | 5 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.68 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.02 € |
| Spread % | 0.42% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-4.16%
- Stock Market
- Warrants
- Warrant
